Puma Biotechnology (PBYI) Net Margin (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Net Margin came in at 8.37% in Q1 2026, down 1484.0% YoY from 0.61% in Q1 2025, and down 137.47% on a QoQ basis from 22.35% in Q4 2025.
Puma Biotechnology (PBYI) Net Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Net Margin data on file, last reported at 8.37% in Q1 2026.
- Quarterly Net Margin fell 1484.0% year-over-year to 8.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.24% (up 897.0% YoY) and the FY2025 annual result came in at 15.12%, up 1520.0% from the prior year.
- Net Margin slipped to 8.37% in Q1 2026, from 22.35% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 25.23% in Q3 2024 to a low of 18.87% in Q4 2024.
- A 5-year average of 4.09% and a median of 3.9% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 9597 bps — and 2024, when it slumped 3611 bps.
- Tracing PBYI's Net Margin over 5 years: stood at 5.88% in 2022, then soared by 393 bps to 17.24% in 2023, then slumped by 209 bps to 18.87% in 2024, then soared by 218 bps to 22.35% in 2025, then slumped by 137 bps to 8.37% in 2026.
- The last three Net Margin figures came in at 8.37% (Q1 2026), 22.35% (Q4 2025), and 16.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 14.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.49% |
| Mar 31, 2026 | -8.37% |
| Dec 31, 2025 | 22.35% |
| Sep 30, 2025 | 16.23% |
| Jun 30, 2025 | 11.17% |
| Mar 31, 2025 | 6.46% |
| Dec 31, 2024 | -18.87% |
| Sep 30, 2024 | 25.23% |
| Jun 30, 2024 | -9.62% |
| Mar 31, 2024 | -11.00% |
| Dec 31, 2023 | 17.24% |
| Sep 30, 2023 | 10.33% |
| Jun 30, 2023 | 3.90% |
| Mar 31, 2023 | 2.65% |
| Dec 31, 2022 | -5.88% |
| Sep 30, 2022 | -0.63% |
| Jun 30, 2022 | 15.74% |
| Mar 31, 2022 | -7.44% |
| Dec 31, 2021 | 7.63% |
| Sep 30, 2021 | -96.60% |